Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release

Kumar, Sandeep; Bhanjana, Gaurav; Verma, Ranjana; Dhingra, Dinesh; Dilbaghi, Neeraj; Kim, Ki‐Hyun

doi:10.1111/jphp.12672

Cited by 88 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug release profile of MN3 shows a sustained release pattern with the passage of time. Same drug release pattern was reported earlier [17]. The encapsulated drug released slowly with the eruption of polymeric layers and completed up to 30 h. The cumulative drug release profile of MN3 and pure metformin is shown in Fig.…”

Section: Dsc Analysissupporting

confidence: 78%

“…Nanoparticulate pharmaceutical formulations have properties of improved bioavailability, controlled, and prolonged drug release time with efficacy, safety and predicted therapeutic effect [5,16]. Various natural, synthetic, and semi-synthetic polymers have been investigated as a drug carrier to utilize the benefits of nanotechnology in formulations [6,[16][17][18][19][20][21]. There is a persistent effort among the researchers to improve the formulation of metformin to attain optimal therapeutic response.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preparation and Characterization of Metformin Loaded Stearic Acid Coupled F127 Nanoparticles

Kamboj

Verma

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The objective of this study was to prepare and evaluate metformin nanoparticles (MN) using stearic acid-coupled F127 (SAF127) copolymer and polyvinyl alcohol by emulsion solvent evaporation technique.Method: Metformin is the first-line drug for the treatment of type II diabetes mellitus belongs to Biopharmaceutical Classification System Class III. The prepared MN was characterized for particle size, polydispersity index (PDI), zeta potential, drug entrapment, percentage yield, in vitro drug release, and stability studies. The compatibility studies were performed by Fourier transform infrared (FTIR) and differential scanning calorimetry (DSC). The crystallographic and surface properties were studied by X-ray diffractometry and scanning electron microscopy, respectively.Results: The mean particle diameter of prepared nanoparticles ranged from 207.8 to 977.64 nm, PDI value ranged from 0.146 to 0.694, and zeta potential ranged from −20.5 to −6.97 mV. The drug entrapment efficiency of these nanoparticles varies between 18.81 to 69.01 %. The drug to SAF127 copolymer (10/30 w/w) ratio (MN3) showed optimum results. The MN3 had spherical morphology with semi-amorphous nature. The results of FTIR and DSC analysis showed that there was no significant interaction between drug and excipients. The prepared polymeric nanoparticles were stable at 5±3°C up to 3 months. In vitro release of drug from MN3 was 20.52% in the first 1 h and remaining drug was released up to 30 h.Conclusion: The results of this study confirmed the sustained drug release profile of metformin loaded SAF127 copolymer nanoparticles. These nanoparticles can be best stored up to 3 months.

show abstract

Section: Dsc Analysissupporting

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Preparation and Characterization of Metformin Loaded Stearic Acid Coupled F127 Nanoparticles

Kamboj

Verma

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…As a decisive fact, diabetes is one of the major causes of disability and death in the world . This disease is a group of metabolic disorders that characterized by high blood sugar levels over a prolonged period.…”

Section: Introductionmentioning

confidence: 99%

“…The short half‐life and low bioavailability of MET make the necessity for the development of de novo drug delivery systems (DDSs) . In this context, dendrimers, liposomes, as well as polymeric micelles can be considered as potential candidates to minimize drug side effects and frequency accumulation as well as augmenting patient compliance …”

Section: Introductionmentioning

confidence: 99%

“…Among these, polymeric micelles are attracted great deal of interest mainly due to their small size, high blood circulation times, maintaining effective plasma drug concentrations, high penetration property through biological membrane, and in vivo stability. In this context, biopolymer‐based micelles have gained a tremendous attention as a potential platform in targeted carriers and modified release in drug delivery …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A de novo formulation of metformin using chitosan‐based nanomicelles for potential diabetes therapy

Abbasian

Bighlari

Mahmoodzadeh

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

A de novo formulation of metformin (MET) was developed through the physical loading of drug into a chitosan-grafted-[poly(acryl amide)-block-poly(acrylic acid)] [CS-g-(PAAm-b-PAA)] terpolymer. For this purpose, CS was functionazed with phthalic anhydride followed by 4-cyano, 4-[(phenylcarbothioyl)sulfanyl]pentanoic acid to produc a macro-RAFT agent (CS-CTA). Afterward, acryl amide and acrylic acid monomers were graft and block copolymerized onto the synthesized CS-CTA through a reversible addition-fragmentation chain transfer (RAFT) polymerization technique to afford CS-g-PAAm copolymer and CS-g-(PAAm-b-PAA) terpolymer, respectively. The fabricated CS-g-(PAAm-b-PAA) terpolymer was loaded with MET as an anti-diabetic drug, and its drug release behavior was evaluated in the body simulated environment. As results, it was concluded that the fabricated CS-g-(PAAm-b-PAA) nanosystem has high potential as de novo drug delivery system (DDS) for diabetes therapy, mainly due to controlled drug release profile in comparison with conventional formulations of MET.

show abstract

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Zhang

Dalan

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

Ischemic heart disease (IHD) is the leading cause of disability and mortality worldwide. Reactive oxygen species (ROS) have been shown to play key roles in the progression of diabetes, hypertension, and hypercholesterolemia, which are independent risk factors that lead to atherosclerosis and the development of IHD. Engineered biomaterial‐based nanomedicines are under extensive investigation and exploration, serving as smart and multifunctional nanocarriers for synergistic therapeutic effect. Capitalizing on cell/molecule‐targeting drug delivery, nanomedicines present enhanced specificity and safety with favorable pharmacokinetics and pharmacodynamics. Herein, the roles of ROS in both IHD and its risk factors are discussed, highlighting cardiovascular medications that have antioxidant properties, and summarizing the advantages, properties, and recent achievements of nanomedicines that have ROS scavenging capacity for the treatment of diabetes, hypertension, hypercholesterolemia, atherosclerosis, ischemia/reperfusion, and myocardial infarction. Finally, the current challenges of nanomedicines for ROS‐scavenging treatment of IHD and possible future directions are discussed from a clinical perspective.

show abstract

Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release

Cited by 88 publications

References 29 publications

Preparation and Characterization of Metformin Loaded Stearic Acid Coupled F127 Nanoparticles

Preparation and Characterization of Metformin Loaded Stearic Acid Coupled F127 Nanoparticles

A de novo formulation of metformin using chitosan‐based nanomicelles for potential diabetes therapy

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Contact Info

Product

Resources

About